Exploratory Study of Pagoclone in Men With Premature Ejaculation.
- Registration Number
- NCT00370981
- Lead Sponsor
- Endo Pharmaceuticals
- Brief Summary
The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.
- Detailed Description
The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 100
- A male regularly experiencing premature ejaculation
- 18 to 55 yrs old
- In a Stable relationship with one woman for at least 6 months
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PBO pagoclone - 0.15 mg pagoclone - 0.60 mg pagoclone - 0.30 mg pagoclone -
- Primary Outcome Measures
Name Time Method Intravaginal ejaculation latency time (IELT)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (16)
Northeast Indiana Research, LLC
🇺🇸Fort Wayne, Indiana, United States
Regional Urology, LLC
🇺🇸Shreveport, Louisiana, United States
SD Uro-Research
🇺🇸San Diego, California, United States
Urology Associates, PC
🇺🇸Denver, Colorado, United States
Urology Centers of Alabama, PC
🇺🇸Homewood, Alabama, United States
Urology Research Options
🇺🇸Aurora, Colorado, United States
Connecticut Clinical Research Center
🇺🇸Waterbury, Connecticut, United States
South Florida Medical Research
🇺🇸Aventura, Florida, United States
Davis Clinic, PC
🇺🇸Indianapolis, Indiana, United States
AccuMed Research Associates
🇺🇸Garden City, New York, United States
Urological Surgeons of Long Island, PC
🇺🇸Garden City, New York, United States
Metrolina Urology Clinic
🇺🇸Charlotte, North Carolina, United States
Center for Urologic Research of WNY
🇺🇸Williamsville, New York, United States
Wake Research Associates, LLC
🇺🇸Raleigh, North Carolina, United States
Johnny B. Roy, MD Private Practice
🇺🇸Edmond, Oklahoma, United States
Mobley Research Center
🇺🇸Houston, Texas, United States